



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

MAY 22 2006

Re: Dutasteride
Docket No.: 2002E-0100

The Honorable Jon Dudas
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 5,565,467, filed by GlaxoSmithKline, under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Dutasteride, the human drug product claimed by the patent.

The total length of the regulatory review period for Dutasteride is 2,373 days. Of this time, 2,038 days occurred during the testing phase and 335 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: May 25, 1995.

The applicant claims April 24, 1995, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was May 25, 1995, which was thirty days after FDA receipt of the IND.

2. The date the application was initially submitted with respect to the human drug product under section 505 of the Federal Food, Drug, and Cosmetic Act: December 21, 2000.

FDA has verified the applicant's claim that the new drug application (NDA) for Dutasteride (NDA 21-319) was initially submitted on December 21, 2000.

3. The date the application was approved: November 20, 2001.


FDA has verified the applicant's claim that NDA 21-319 was approved on November 20, 2001.

Dudas - Dutasteride - page 2

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,



Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: David J. Levy, Ph.D.
GlaxoSmithKline
Corporate Intellectual Property Dept.
Five Moore Dr., P.O. Box 13398
Research Triangle Park, NC 27709-3308